Lit­tle Aldeyra's shares rock­et high­er as its first PhI­II eye drug tri­al scores, clear­ing path to NDA

Aldeyra Ther­a­peu­tics’ first for­ay in­to Phase III is a suc­cess, the eye drug de­vel­op­er said, set­ting it up for a po­ten­tial NDA fil­ing by the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.